CellSeed Inc.
Tokyo Stock Exchange 7776.T
CellSeed Inc. Price to Sales Ratio (P/S) on January 14, 2025: 59.53
-
CellSeed Inc. 52-week high Price to Sales Ratio (P/S) is 175.16 on July 17, 2024, which is 194.23% above the current Price to Sales Ratio (P/S).
-
CellSeed Inc. 52-week low Price to Sales Ratio (P/S) is 32.91 on April 25, 2024, which is -44.72% below the current Price to Sales Ratio (P/S).
-
CellSeed Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 73.18.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Ms. Setsuko Hashimoto Ph.D. |
| IPO Date | March 16, 2010 |
| Location | Japan |
| Headquarters | Telecom Center Building |
| Employees | 44 |
| Sector | Health Care |
| Industries | |
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email